UK – GSK’s Blenrep combination recommended by NICE to treat multiple myeloma
GSK’s Blenrep (belantamab mafodotin) has been recommended by the National Institute for Health and Care Excellence (NICE) as part of a combination treatment for multiple myeloma (MM).
The health technology assessment agency has recommended in draft guidance that the antibody-drug conjugate be used on the NHS alongside bortezomib plus dexamethasone (BVd) as a second-line MM treatment for adults who are refractory to, or intolerant of, lenalidomide.
The decision means that eligible patients will be the first in the world to access the combination.
More information on PMLiVE.
OpenEdition vous propose de citer ce billet de la manière suivante :
vroby (28 juillet 2025). UK – GSK’s Blenrep combination recommended by NICE to treat multiple myeloma. ELSIBI. Consulté le 19 février 2026 à l’adresse https://doi.org/10.58079/14fyr





